Adoptive cell therapy: past, present and future

References

• 1 Pages F, Galon J, Dieu-Nosjean MC, Tartour E, Sautes-Fridman C, Fridman WH. Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene 29(8), 1093–1102 (2009).
  MedlineGoogle Scholar
• 2 Mitchison NA. Passive transfer of transplantation immunity. Nature 171(4345), 267–268 (1953).
  Medline CASGoogle Scholar
• 3 Fefer A, Einstein AB, Cheever MA. Adoptive chemoimmunotherapy of cancer in animals: a review of results, principles, and problems*. Ann. NY Acad. Sci. 277(1), 492–504 (1976).
  Medline CASGoogle Scholar
• 4 Robb RJ, Kutny RM, Chowdhry V. Purification and partial sequence analysis of human T-cell growth factor. Proc. Natl Acad. Sci. USA 80(19), 5990–5994 (1983).
  Medline CASGoogle Scholar
• 5 Rosenberg SA, Barry JM. The Transformed Cell: Unlocking the Mysteries of Cancer. Putnam Adult, NY, USA (1992).
  Google Scholar
• 6 Aldesleukin Product Approval Information – Licensing Action. www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/ucm080733.htm.
  Google Scholar
• 7 Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233(4770), 1318–1321 (1986).
  Medline CASGoogle Scholar
• 8 Brandes L, Galton DaG, Wiltshaw E. Originally published as Volume 2, Issue 7719 New approach to immunotherapy of melanoma. Lancet 298(7719), 293–295 (1971).
  Google Scholar
• 9 McPeak CJ. Intralymphatic therapy with immune lymphocytes. Cancer 28(5), 1126–1128 (1971).
  Medline CASGoogle Scholar
• 10 Atkins MB, Lotze MT, Dutcher JP et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J. Clin. Oncol. 17(7), 2105 (1999).
  Medline CASGoogle Scholar
• 11 Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J. Sci. Am. 6(Suppl. 1), S11–S14 (2000).
  MedlineGoogle Scholar
• 12 Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes and recombinant interleukin-2: a pilot study. J. Clin. Oncol. 6(5), 839–853 (1988).
  Medline CASGoogle Scholar
• 13 Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N. Engl. J. Med. 319(25), 1676–1680 (1988).
  Medline CASGoogle Scholar
• 14 Rosenberg SA, Yannelli JR, Yang JC et al. Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2. J. Natl Cancer Inst. 86(15), 1159–1166 (1994).
  Medline CASGoogle Scholar
• 15 Slavin S, Nagler A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 91(3), 756–763 (1998).
  Medline CASGoogle Scholar
• 16 Dudley ME, Wunderlich JR, Yang JC et al. A Phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J. Immunother. 25(3), 243–251 (2002).
  Medline CASGoogle Scholar
• 17 Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298(5594), 850–854 (2002).
  Medline CASGoogle Scholar
• 18 Dudley ME, Wunderlich JR, Yang JC et al. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23(10), 2346–2357 (2005).
  Medline CASGoogle Scholar
• 19 Zaretsky JM, Garcia-Diaz A, Shin DS et al. Mutations associated with acquired resistance to PD-1 blockade in melanoma. N. Engl. J. Med. doi:10.1056/NEJMoa1604958 (2016) (Epub ahead of print).
  MedlineGoogle Scholar
• 20 Dudley ME, Yang JC, Sherry R et al. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26(32), 5233–5239 (2008).
  Medline CASGoogle Scholar
• 21 Gattinoni L, Finkelstein SE, Klebanoff CA et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8⁺ T cells. J. Exp. Med. 202(7), 907–912 (2005).
  Medline CASGoogle Scholar
• 22 Goff SL, Dudley ME, Citrin DE et al. Randomized, prospective evaluation comparing intensity of lymphodepletion before adoptive transfer of tumor-infiltrating lymphocytes for patients with metastatic melanoma. J. Clin. Oncol. 34(20), 2389–2397 (2016).
  MedlineGoogle Scholar
• 23 Antony PA, Piccirillo CA, Akpinarli A et al. CD8⁺ T cell immunity against a tumor/self-antigen is augmented by CD4⁺ T helper cells and hindered by naturally occurring T regulatory cells. J. Immunol. 174(5), 2591–2601 (2005).
  Medline CASGoogle Scholar
• 24 Paulos CM, Wrzesinski C, Kaiser A et al. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8⁺ T cells via TLR4 signaling. J. Clin. Invest. 117(8), 2197–2204 (2007).
  Medline CASGoogle Scholar
• 25 Sivan A, Corrales L, Hubert N et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy. Science 350(6264), 1084–1089 (2015).
  Medline CASGoogle Scholar
• 26 Vetizou M, Pitt JM, Daillere R et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. Science 350(6264), 1079–1084 (2015).
  Medline CASGoogle Scholar
• 27 Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J. Sci. Am. 6(Suppl. 1), S55–57 (2000).
  MedlineGoogle Scholar
• 28 Nishikawa H, Sakaguchi S. Regulatory T cells in cancer immunotherapy. Curr. Opin. Immunol. 27, 1–7 (2014).
  Medline CASGoogle Scholar
• 29 Hirakawa M, Matos T, Liu H et al. Low-dose IL-2 selectively activates subsets of CD4⁺ Tregs and NK cells. JCI Insight 1(18), e89278 (2016).
  MedlineGoogle Scholar
• 30 Goedegebuure PS, Douville LM, Li H et al. Adoptive immunotherapy with tumor-infiltrating lymphocytes and interleukin-2 in patients with metastatic malignant melanoma and renal cell carcinoma: a pilot study. J. Clin. Oncol. 13(8), 1939–1949 (1995).
  Medline CASGoogle Scholar
• 31 Ellebaek E, Iversen TZ, Junker N et al. Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients. J. Transl. Med. 10, 169 (2012).
  Medline CASGoogle Scholar
• 32 Yee C, Thompson JA, Byrd D et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc. Natl Acad. Sci. USA 99(25), 16168–16173 (2002).
  Medline CASGoogle Scholar
• 33 Besser MJ, Shapira-Frommer R, Itzhaki O et al. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies. Clin. Cancer Res. 19(17), 4792–4800 (2013).
  Medline CASGoogle Scholar
• 34 Joseph RW, Peddareddigari VR, Liu P et al. Impact of clinical and pathologic features on tumor-infiltrating lymphocyte expansion from surgically excised melanoma metastases for adoptive T-cell therapy. Clin. Cancer Res. 17(14), 4882–4891 (2011).
  Medline CASGoogle Scholar
• 35 Ben-Avi R, Itzhaki O, Simansky D et al. Metastatic lung lesions as a preferred resection site for immunotherapy with tumor infiltrating lymphocytes. J. Immunother. 39(5), 218–222 (2016).
  Medline CASGoogle Scholar
• 36 Goff SL, Smith FO, Klapper JA et al. Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. J. Immunother. 33(8), (2010).
  MedlineGoogle Scholar
• 37 Chacon JA, Pilon-Thomas S, Sarnaik AA, Radvanyi LG. Continuous 4–1BB co-stimulatory signals for the optimal expansion of tumor-infiltrating lymphocytes for adoptive T-cell therapy. Oncoimmunology 2(9), e25581 (2013).
  MedlineGoogle Scholar
• 38 Hernandez-Chacon JA, Li Y, Wu RC et al. Costimulation through the CD137/4–1BB pathway protects human melanoma tumor-infiltrating lymphocytes from activation-induced cell death and enhances antitumor effector function. J. Immunother. 34(3), 236–250 (2011).
  Medline CASGoogle Scholar
• 39 Liu S, Etto T, Rodriguez-Cruz T et al. TGF-beta1 induces preferential rapid expansion and persistence of tumor antigen-specific CD8⁺ T cells for adoptive immunotherapy. J. Immunother. 33(4), 371–381 (2010).
  Medline CASGoogle Scholar
• 40 Robbins PF, Dudley ME, Wunderlich J et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J. Immunol. 173(12), 7125–7130 (2004).
  Medline CASGoogle Scholar
• 41 Fisher B, Packard BS, Read EJ et al. Tumor localization of adoptively transferred indium-111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma. J. Clin. Oncol. 7(2), 250–261 (1989).
  Medline CASGoogle Scholar
• 42 Cole DJ, Taubenberger JK, Pockaj BA et al. Histopathological analysis of metastatic melanoma deposits in patients receiving adoptive immunotherapy with tumor-infiltrating lymphocytes. Cancer Immunol. Immunother. 38(5), 299–303 (1994).
  Medline CASGoogle Scholar
• 43 Pockaj BA, Sherry RM, Wei JP et al. Localization of ¹¹¹indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Augmentation with cyclophosphamide and correlation with response. Cancer 73(6), 1731–1737 (1994).
  Medline CASGoogle Scholar
• 44 Shen X, Zhou J, Hathcock KS et al. Persistence of tumor infiltrating lymphocytes in adoptive immunotherapy correlates with telomere length. J. Immunother. 30(1), 123–129 (2007).
  Medline CASGoogle Scholar
• 45 Radvanyi LG, Bernatchez C, Zhang M et al. Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patients. Clin. Cancer Res. 18(24), 6758–6770 (2012).
  Medline CASGoogle Scholar
• 46 Heemskerk B, Liu K, Dudley ME et al. Adoptive cell therapy for patients with melanoma, using tumor-infiltrating lymphocytes genetically engineered to secrete interleukin-2. Hum. Gene Ther. 19(5), 496–510 (2008).
  Medline CASGoogle Scholar
• 47 Robbins PF, Kassim SH, Tran TL et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21(5), 1019–1027 (2014).
  MedlineGoogle Scholar
• 48 Dudley ME, Gross CA, Langhan MM et al. CD8⁺ enriched “young” tumor infiltrating lymphocytes can mediate regression of metastatic melanoma. Clin. Cancer Res. 16(24), 6122–6131 (2010).
  Medline CASGoogle Scholar
• 49 Donia M, Junker N, Ellebaek E, Andersen MH, Straten PT, Svane IM. Characterization and comparison of ‘standard’ and ‘young’ tumour-infiltrating lymphocytes for adoptive cell therapy at a Danish translational research institution. Scand. J. Immunol. 75(2), 157–167 (2012).
  Medline CASGoogle Scholar
• 50 Dudley ME, Gross CA, Somerville RP et al. Randomized selection design trial evaluating CD8⁺-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J. Clin. Oncol. 31(17), 2152–2159 (2013).
  Medline CASGoogle Scholar
• 51 Friedman KM, Prieto PA, Devillier LE et al. Tumor-specific CD4⁺ melanoma tumor-infiltrating lymphocytes. J. Immunother. 35(5), 400–408 (2012).
  Medline CASGoogle Scholar
• 52 Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4⁺ T Cells against NY-ESO-1. N. Engl. J. Med. 358(25), 2698–2703 (2008).
  Medline CASGoogle Scholar
• 53 Chandran SS, Paria BC, Srivastava AK, Rothermel LD, Stephens DJ, Kammula US. Tumor-specific effector CD8⁺ T cells that can establish immunological memory in humans after adoptive transfer are marked by expression of IL7 receptor and c-myc. Cancer Res. 75(16), 3216–3226 (2015).
  Medline CASGoogle Scholar
• 54 Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat. Immunol. 4(12), 1191–1198 (2003).
  Medline CASGoogle Scholar
• 55 Ilyas S, Yang JC. Landscape of tumor antigens in t cell immunotherapy. J. Immunol. 195(11), 5117–5122 (2015).
  Medline CASGoogle Scholar
• 56 Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314(5796), 126 (2006).
  Medline CASGoogle Scholar
• 57 Johnson LA, Morgan RA, Dudley ME et al. Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen. Blood 114(3), 535 (2009).
  Medline CASGoogle Scholar
• 58 Morgan RA, Chinnasamy N, Abate-Daga DD et al. Cancer regression and neurologic toxicity following anti-MAGE-A3 TCR gene therapy. J. Immunother. (Hagerstown, Md: 1997) 36(2), 133–151 (2013).
  Medline CASGoogle Scholar
• 59 Robbins PF, Kassim SH, Tran TL et al. A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response. Clin. Cancer Res. 21(5), 1019–1027 (2015).
  Medline CASGoogle Scholar
• 60 Parkhurst MR, Yang JC, Langan RC et al. T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis. Mol. Ther. 19(3), 620–626 (2011).
  Medline CASGoogle Scholar
• 61 Linette GP, Stadtmauer EA, Maus MV et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood 122(6), 863–871 (2013).
  Medline CASGoogle Scholar
• 62 Robbins PF, Lu Y-C, El-Gamil M et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. Nat. Med. 19(6), 747–752 (2013).
  Medline CASGoogle Scholar
• 63 Tran E, Turcotte S, Gros A et al. Cancer immunotherapy based on mutation-specific CD4⁺ T cells in a patient with epithelial cancer. Science 344(6184), 641 (2014).
  Medline CASGoogle Scholar
• 64 Shao H, Zhang W, Hu Q, Wu F, Shen H, Huang S. TCR mispairing in genetically modified T cells was detected by fluorescence resonance energy transfer. Mol. Biol. Rep. 37(8), 3951–3956 (2010).
  Medline CASGoogle Scholar
• 65 Reuß S, Sebestyén Z, Heinz N et al. TCR-engineered T cells: a model of inducible TCR expression to dissect the interrelationship between two TCRs. Eur. J. Immunol. 44(1), 265–274 (2014).
  Medline CASGoogle Scholar
• 66 Bunse M, Bendle GM, Linnemann C et al. RNAi-mediated TCR knockdown prevents autoimmunity in mice caused by mixed TCR dimers following TCR gene transfer. Mol. Ther. 22(11), 1983–1991 (2014).
  Medline CASGoogle Scholar
• 67 Govers C, Sebestyã NZ, Roszik JN et al. TCRs genetically linked to CD28 and CD3Îμ do not mispair with endogenous TCR chains and mediate enhanced T cell persistence and anti-melanoma activity. J. Immunol. 193(10), 5315–5326 (2014).
  Medline CASGoogle Scholar
• 68 Peng W, Ye Y, Rabinovich BA et al. Transduction of tumor-specific T cells with CXCR2 chemokine receptor improves migration to tumor and antitumor immune responses. Clin. Cancer Res. 16(22), 5458–5468 (2010).
  Medline CASGoogle Scholar
• 69 Sapoznik S, Ortenberg R, Galore-Haskel G et al. CXCR1 as a novel target for directing reactive T cells toward melanoma: implications for adoptive cell transfer immunotherapy. Cancer Immunol. Immunother. 61(10), 1833–1847 (2012).
  Medline CASGoogle Scholar
• 70 Zhang L, Morgan RA, Beane JD et al. Tumor-infiltrating lymphocytes genetically engineered with an inducible gene encoding interleukin-12 for the immunotherapy of metastatic melanoma. Clin. Cancer Res. 21(10), 2278–2288 (2015).
  Medline CASGoogle Scholar
• 71 Pato A, Eisenberg G, Machlenkin A et al. Messenger RNA encoding constitutively active Toll-like receptor 4 enhances effector functions of human T cells. Clin. Exp. Immunol. 182(2), 220–229 (2015).
  Medline CASGoogle Scholar
• 72 Amos SM, Pegram HJ, Westwood JA et al. Adoptive immunotherapy combined with intratumoral TLR agonist delivery eradicates established melanoma in mice. Cancer Immunol. Immunother. 60(5), 671–683 (2011).
  Medline CASGoogle Scholar
• 73 Gross G, Waks T, Eshhar Z. Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc. Natl Acad. Sci. USA 86(24), 10024–10028 (1989).
  Medline CASGoogle Scholar
• 74 Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z. Targeting of T lymphocytes to Neu/HER2-expressing cells using chimeric single chain Fv receptors. J. Immunol. 151(11), 6577–6582 (1993).
  Medline CASGoogle Scholar
• 75 Lee DW, Kochenderfer JN, Stetler-Stevenson M et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a Phase 1 dose-escalation trial. Lancet 385(9967), 517–528 (2015).
  Medline CASGoogle Scholar
• 76 Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N. Engl. J. Med. 371(16), 1507–1517 (2014).
  Medline CASGoogle Scholar
• 77 Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci. Transl. Med. 5(177), 177ra138 (2013).
  Google Scholar
• 78 Kochenderfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J. Clin. Oncol. 33(6), 540–549 (2015).
  Medline CASGoogle Scholar
• 79 Brudno JN, Somerville RPT, Shi V et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell transplantation without causing graft-versus-host disease. J. Clin. Oncol. 34(10), 1112–1121 (2016).
  Medline CASGoogle Scholar
• 80 Yvon E, Del Vecchio M, Savoldo B et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin. Cancer Res. 15(18), 5852–5860 (2009).
  Medline CASGoogle Scholar
• 81 Prapa M, Caldrer S, Spano C et al. A novel anti-GD2/4–1BB chimeric antigen receptor triggers neuroblastoma cell killing. Oncotarget 6(28), 24884–24894 (2015).
  MedlineGoogle Scholar
• 82 Lo AS, Ma Q, Liu DL, Junghans RP. Anti-GD3 chimeric sFv-CD28/T-cell receptor zeta designer T cells for treatment of metastatic melanoma and other neuroectodermal tumors. Clin. Cancer Res. 16(10), 2769–2780 (2010).
  Medline CASGoogle Scholar
• 83 Louis CU, Savoldo B, Dotti G et al. Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood 118(23), 6050–6056 (2011).
  Medline CASGoogle Scholar
• 84 Morello A, Sadelain M, Adusumilli PS. Mesothelin-targeted CARs: driving T cells to solid tumors. Cancer Discov. 6(2), 133–146 (2016).
  Medline CASGoogle Scholar
• 85 Beatty GL, Haas AR, Maus MV et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol. Res. 2(2), 112–120 (2014).
  Medline CASGoogle Scholar
• 86 Janos Laszlo Tanyi, Andrew R Haas, Gregory Lawrence Beatty et al. Anti-mesothelin chimeric antigen receptor T cells in patients with epithelial ovarian cancer. Presented at: 2016 ASCO Annual Meeting. J. Clin. Oncol. 34(Suppl. Abstract 5511), (2016).
  Google Scholar
• 87 Di Stasi A, Tey S-K, Dotti G et al. Inducible apoptosis as a safety switch for adoptive cell therapy. N. Engl. J. Med. 365(18), 1673–1683 (2011).
  Medline CASGoogle Scholar
• 88 Adusumilli PS, Cherkassky L, Villena-Vargas J et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci. Transl. Med. 6(261), 261ra151 (2014).
  MedlineGoogle Scholar
• 89 Katz SC, Burga RA, Mccormack E et al. Phase I hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor-modified T-cell therapy for CEA+ liver metastases. Clin. Cancer Res. 21(14), 3149–3159 (2015).
  Medline CASGoogle Scholar
• 90 Katz SC, Point GR, Cunetta M et al. Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery. Cancer Gene Ther. 23(5), 142–148 (2016).
  Medline CASGoogle Scholar
• 91 Ma Q, Gomes EM, Lo AS, Junghans RP. Advanced generation anti-prostate specific membrane antigen designer T cells for prostate cancer immunotherapy. Prostate 74(3), 286–296 (2014).
  Medline CASGoogle Scholar
• 92 Zuccolotto G, Fracasso G, Merlo A et al. PSMA-specific CAR-engineered T cells eradicate disseminated prostate cancer in preclinical models. PLoS ONE 9(10), e109427 (2014).
  MedlineGoogle Scholar
• 93 Rafiq S, Dao T, Liu C, Scheinberg DA, Brentjens RJ. Engineered T cell receptor-mimic antibody, (TCRm) chimeric antigen receptor (CAR) T cells against the intracellular protein Wilms tumor-1 (WT1) for treatment of hematologic and solid cancers. Blood 124(21), 2155–2155 (2014).
  Google Scholar
• 94 Sommermeyer D, Hudecek M, Kosasih PL et al. Chimeric antigen receptor-modified T cells derived from defined CD8⁺ and CD4⁺ subsets confer superior antitumor reactivity in vivo. Leukemia 30(2), 492–500 (2016).
  Medline CASGoogle Scholar
• 95 Turtle CJ, Hanafi LL-aC, Berger C et al. CD19 CAR-T cells of defined CD4⁺: CD8⁺ composition in adult B cell ALL patients. J. Clin. Invest. 126(6), 2123–2138 (2016).
  MedlineGoogle Scholar
• 96 Sabatino M, Hu J, Sommariva M et al. Generation of clinical-grade CD19-specific CAR-modified CD8⁺ memory stem cells for the treatment of human B-cell malignancies. Blood 128(4), 519–528 (2016).
  Medline CASGoogle Scholar
• 97 Savoldo B, Ramos CA, Liu E et al. CD28 costimulation improves expansion and persistence of chimeric antigen receptor modified T cells in lymphoma patients. J. Clin. Invest. 121(5), 1822–1826 (2011).
  Medline CASGoogle Scholar
• 98 Imai C, Mihara K, Andreansky M et al. Chimeric receptors with 4–1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia. Leukemia 18(4), 676–684 (2004).
  Medline CASGoogle Scholar
• 99 Cherkassky L, Morello A, Villena-Vargas J et al. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J. Clin. Invest. 126(8), 3130–3144 (2016).
  MedlineGoogle Scholar
• 100 Bendle GM, Linnemann C, Bies L, Song JY, Schumacher TN. Blockade of TGF-beta signaling greatly enhances the efficacy of TCR gene therapy of cancer. J. Immunol. 191(6), 3232–3239 (2013).
  Medline CASGoogle Scholar
• 101 Rosenberg SA, Yang JC, Sherry RM et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clin. Cancer Res. 17(13), 4550–4557 (2011).
  Medline CASGoogle Scholar